Medical equipment: balancing cost, compliance and sustainability

Medical equipment suppliers are being pulled three ways. Input costs jumped in 2026. Regulatory rules on both sides of the Channel are being rewritten. And the biggest UK customer, the NHS, is changing how it buys and what it asks suppliers to prove about carbon. The good news is that some of these pressures now point in the same direction. The checklist below is built around that.

Where things stand

On regulation, the most recent change is helpful. On 21 October 2026 the government confirmed that the MHRA will continue to accept CE-marked medical devices in Great Britain on a long-term basis, without an extra UK approval route. Browne Jacobson notes that more than 90% of devices registered for use in Great Britain carry a CE mark. UKCA remains the domestic route.

Post-market obligations went the other way and got tighter. New post-market surveillance regulations took effect in Great Britain on 16 June 2025, bringing shorter deadlines for reporting serious incidents and a duty to report trends in incidents that individually fall below the serious threshold.

In the EU, the Commission published a proposal on 16 December 2025 to simplify the MDR and IVDR. As summarised by Simmons & Simmons, it would allow certificates to run beyond the current five-year limit, reduce audit frequency for lower-risk devices, and move periodic safety update reports for Class IIb and III devices to every two years. At publication, the text was still open to amendment.

On the buying side, the 10 Year Health Plan for England, published in summer 2025, set a national shift towards value-based procurement and said NICE would extend its technology appraisal process to devices, diagnostics and digital products from April 2026. NHS England's net zero supplier roadmap applies a minimum 10% weighting for net zero and social value in its procurements. Pinsent Masons sets out the next steps: from April 2027, suppliers to new procurements worth £5 million or more a year must publicly report emissions and targets and publish a carbon reduction plan covering global Scope 1, 2 and 3 emissions, with product-level carbon footprint requirements expected from 2028.

Costs, meanwhile, have risen sharply. The ONS reported manufacturers' input prices up 8.3% in the year to September 2026, driven by oil, and services prices for transportation and storage up 10.7% in the third quarter. Packaging Gateway reported polypropylene and polyethylene up more than 30% since late February 2026. Those polymers run through single-use devices, sterile barrier packaging and trays.

A checklist for the next two quarters

Map your regulatory exposure by product family. The CE decision removes a cliff edge for many GB product lines. It also means the EU rules, including whatever simplification is finally adopted, now set the pace for most of your portfolio. Keep a single view of each family's certificate expiry, notified body and recertification plan.

Test post-market surveillance against the new deadlines. Shorter serious incident timelines expose slow complaint handling. Check how long it takes for a field complaint to reach the person who decides whether it is reportable. Trend reporting also needs data that is joined up across distributors and service teams.

Rebuild the bill of materials cost. With resin and freight moving this much, last year's standard costs are probably wrong. Reprice the top 20 SKUs by revenue against current polymer and freight rates and see which contracts are now loss-making.

Get ahead of the April 2027 carbon reporting. Scope 3 reporting for medical devices is mostly about purchased materials, components and logistics. Your suppliers' data will be the hard part, so start the requests now rather than in March 2027.

Prepare for product carbon footprints in 2028. Pick two or three high-volume products and run a footprint now, even a rough one. It will show where the emissions sit, and usually that is in materials and packaging, which are also where the cost increases are.

Make the value-based case in the buyer's language. Value-based procurement rewards suppliers who can show total cost across a care pathway rather than unit price alone. That includes reprocessing, waste, storage and staff time. Build that evidence for your core products before the next framework round.

Look again at packaging and sterile barrier specifications. Lighter, mono-material packaging can cut resin cost, freight cost and embedded carbon together, provided validation and sterility requirements are met. That last condition means planning the change through quality and regulatory, not around them.

Who should own this

These items cut across quality and regulatory, procurement, operations and commercial teams. In most mid-sized medtech businesses nobody owns the combined picture. Give one senior person accountability for the trade-offs between cost, compliance and carbon, with a monthly view of all three. Otherwise each function will optimise its own number and the NHS bid team will be left to explain the gaps.

The ideal setup would be to bring all these conversations into the S&OP process, ensuring that every decision and every demand-supply alignment takes these considerations into account. This would help the business move beyond short-term trade-offs towards a more integrated, forward-looking plan that balances these items, rather than treating each as a separate priority.